The latest developments from pharmaceutical and biopharmaceutical companies, both innovator and generic-drug companies, and leading regulatory news.
Mylan has launched a generic version of Biogen's Tecfidera (dimethyl fumarate), a drug for treating relapsing multiple sclerosis (MS). Tecfidera is Biogen’s top-selling drug with 2019 global sales of $4.4 billion.
Mylan is launching dimethyl...
Eli Lilly and Company and Innovent Biologics, a Suzhou, China-based biopharmaceutical company, have announced a global expansion of their strategic alliance for TYVYT (sintilimab), an anti-PD-1 monoclonal antibody immuno-oncology medicine, in a...
Johnson & Johnson (J&J) has agreed to acquire Momenta Pharmaceuticals, a Cambridge, Massachusetts-based company developing biosimilars and new biologics for rare immune-mediated diseases, for $6.5 billion.
Momenta’s lead asset is...
Gilead Sciences and Tango Therapeutics, a Cambridge, Massachusetts-based company developing cancer therapies, have expanded their strategic collaboration to discover, develop, and commercialize targeted immune-evasion therapies for cancer in a deal...
Bristol Myers Squibb (BMS) and Dragonfly Therapeutics, a Waltham, Massachusetts-based company specializing in cancer immunotherapies, have formed a collaboration, worth up to $475 million, for Dragonfly’s immunotherapy candidate, DF6002, for...
AstraZeneca has concluded an agreement with the European Commission (EC) to supply up to 400 million doses of AZD1222, the COVID-19 vaccine co-invented by the University of Oxford and its spinout company, Vaccitech, and licensed by...
Thermo Fisher Scientific reports that its $12-billion-plus offer to Qiagen, a provider of molecular diagnostics and sample preparation technologies, has lapsed after failing to acquire the needed number of shares to effectuate the...
The latest on manufacturing and potential treatments for COVID-19 with news from Pfizer, Gilead Sciences, AstraZeneca, Takeda, Novavax, Daiichi Sankyo, and others.
Pfizer in Pact to Manufacture Gilead’s Remdesivir for COVID-19Pfizer has entered...
Eisai's US subsidiary, Eisai Inc., has announced plans to re-locate its US headquarters in Woodcliff Lake, New Jersey to the former Roche headquarters campus in Nutley, New Jersey. The move is expected to be completed in late 2021 and will transfer...
Moderna, a clinical-stage biopharmaceutical company developing messenger RNA (mRNA) therapeutics and vaccines, has been awarded up to $1.525 billion, including incentive payments, by the US government to manufacture and deliver 100 million doses of...
The US government is putting on hold a $765-million loan to Eastman Kodak Company, which was to be used to launch Kodak Pharmaceuticals, a new arm of the company to produce generic active pharmaceutical ingredients (APIs) in the US, pending a...
Bayer has agreed to acquire KaNDy Therapeutics, a Stevenage, UK-based clinical-stage biopharmaceutical company, to expand its drug-development pipeline in women’s healthcare, in a deal worth up to $875 million.
KaNDy Therapeutics recently...
A roundup of news from Germany (Evotec, Secarna Pharmaceuticals, CureVac), Japan (Teva, Takeda), and the US (Astellas, Sorrento Therapeutics, and SRI Biosciences).
Germany
Evotec, Secarna Pharmaceuticals in Pact for Antisense...
The latest on manufacturing and potential treatments for COVID-19 with news from Eli Lilly and Company, Pfizer, Amgen, AbbVie, Takeda, BioNTech, Novavax, and others.
Lilly Initiates Phase III Trial of Monoclonal Antibody for COVID-19 Eli Lilly and...
Novartis and Sangamo Therapeutics, a Brisbane, California-based genomic medicine company, have formed a global licensing collaboration agreement, worth up to $795 million, to develop and commercialize gene-regulation therapies to address three...
